Influence of Antiretroviral Therapy on the Metabolic Profile of People Living with HIV Followed at University Hospital, Cotonou, Benin
Influence of Antiretroviral Therapy on the Metabolic Profile of People Living with HIV Followed at University Hospital, Cotonou, Benin作者机构：Internal Medicine Department National University Hospital (CNHU-Hubert K. Maga) Cotonou Benin Ambulatory Care Center for People Living with HIV at CNHU-Hubert K. Maga Cotonou Benin Internal Medicine Department Prefectural University Hospital of Borgou Parakou Benin Endocrinology and Metabolic Diseases Department at CNHU-Hubert K. Maga Cotonou Benin Cardiology Department CNHU-Hubert K. Maga Cotonou Benin
出 版 物：《Open Journal of Internal Medicine》 (内科学期刊（英文）)
年 卷 期：2015年第5卷第4期
页 面：106-114页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Metabolic Syndrome Diabetes Dyslipidemia Antiretroviral Therapy HIV Infection
摘 要：Introduction: Since the advent of antiretroviral therapy, the vital prognosis of people living with HIV (PLWHA) has improved significantly. However, the risk of metabolic complications is high, thus making the bed of cardiovascular disease. Our objective was to compare the prevalence of metabolic abnormalities among PLWHA receiving ARVs to that observed in those who are not treated. Methods: We conducted a cross-sectional study (January to April 2010) at the PLWHA ambulatory care center of national university hospital (CNHU-Hubert K. Maga) in Cotonou, Bénin. We recruited 420 PLWHA (210 treated for at least 6 months and 210 untreated). We determined the prevalence of metabolic syndrome (MS) defined by the criteria of NCEP-ATP III, and the prevalence of abnormal glucose and lipid, and lipodystrophy. Association between metabolic syndrome and ARVs used was analyzed by binomial regression. Confidence intervals were calculated at 95% and 5% alpha level. Results: The prevalence of MS was 16% (18% of patients treated vs. 13% of non-treated, p = 0.18). That of hyperglycemia was 18% (30% of patients treated vs. 6% of untreated;p 0.001) and of diabetes 7% (12% of patients treated vs 2% of untreated;p 0.0001). The total cholesterol prevalence was 29% (44% of treated vs 13% of untreated;p 0.02). That of lipodystrophy in 210 patients was 29% (lipoatrophy16%, lipohypertrophy 8%, mixed form 6%). Factors associated with metabolic syndrome were age, hypertension, diabetes (personal or family), BMI, exposure to stavudine (OR = 1.59 [1.02 to 2.47], p = 0.04) and indinavir booted with ritonavir (OR = 2.23 [1.11 to 4 46], p = 0.02). Conclusion: The metabolic abnormalities are more common in PLWHA treated with ARVs. Preventing these anomalies should be made to the initiation of antiretroviral therapy and during the therapeutic monitoring.
维普期刊数据库